ADXN Stock — Addex Therapeutics Ltd

Addex Therapeutics Ltd (ADXN)

Updated October 16, 2026.

ADXN is a Stock. Total return is 153233.3% over the past 6.7 years, 153076.3 points ahead of SPY at 157.0%.

Addex Therapeutics Ltd is a Swiss biopharmaceutical company that discovers and develops small-molecule drugs targeting G-protein coupled receptors and enzymes for neurological disorders, including programs in clinical trials for Parkinson's disease, stroke recovery, and conditions like chronic pain and addiction. The company does not currently distribute dividends. Addex operates through partnerships with major pharmaceutical firms including Janssen Pharmaceuticals and Indivior, funding its drug development pipeline through collaboration agreements and capital raises rather than earnings.

ADXN performance versus SPY

Price and return data through 2026-10-16.

Total return is 153233.3% over the past 6.7 years, 153076.3 points ahead of SPY at 157.0%. Over the past year its total return — price change plus distributions reinvested — is -67.6%. Its deepest 1-year drawdown was 75.8%.

ADXN key facts

Asset type

Stock

Asset class

Equity

Inception date

01/29/2020

Distribution frequency

None

Last close

$2.76 (as of 2026-10-16)

Market cap

$4,836,721

Average volume

11328.0

Beta

2.02

Payout ratio

0.0%

EPS

$-7.56

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADXN risks and drawbacks

The deepest 1-year drawdown on record here is 75.8%.

Who may consider ADXN — and who may not

It is a weaker fit for investors who need monthly cash flow (ADXN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ADXN

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions